Psilocybin Shows Promise in Temporarily Restoring Functions in Advanced Alzheimer’s Disease.
New Case Report Reveals
In a striking case that challenges long-held assumptions about the irreversibility of advanced neurodegeneration, an 80-year-old woman with severe Alzheimer’s disease experienced significant, though temporary, improvements in speech, memory, mobility, and daily functioning after receiving a high dose of psilocybin-containing mushrooms.
The woman, who had lived with Alzheimer’s symptoms for nearly a decade and had been largely silent and dependent on caregivers for the past five years, received a supervised 5-gram dose of psilocybin mushrooms (Enigma strain) in Brazil.
Within about 19–20 hours, she began speaking in full sentences, recalling detailed personal memories, regaining bladder control, dressing herself independently, and engaging socially with eye contact and emotional responsiveness.
These gains persisted for weeks, allowing her to walk with greater agility, retrieve contextual memories, and participate in conversations.
A follow-up 3-gram dose further enhanced effects, including moments of humor and vivid recollections, such as describing surfing with her son.
The improvements were not permanent and eventually faded, but the case suggests that in advanced Alzheimer’s, some cognitive and functional abilities may not be entirely erased by neurodegeneration but could instead be rendered inaccessible—potentially “unlocked” through mechanisms like psilocybin’s effects on neuroplasticity, serotonin receptors, and brain network connectivity.
Details from the Case Report
Published in Frontiers in Neuroscience, the exploratory observational case report details the woman’s journey under careful medical supervision.
Researchers noted initial effects including agitation and a prolonged sleep-like state, followed by the remarkable functional revival. No brain imaging confirmed structural reversal of Alzheimer’s pathology, and the authors emphasize this is a single case, not evidence of a cure.
However, it highlights psilocybin’s potential to promote transient multidomain recovery even in late-stage disease.
Broader Context and Implications
Alzheimer’s disease currently affects millions worldwide, with limited treatments that slow progression but do little to restore lost abilities in advanced stages. Psychedelics like psilocybin have gained attention for their roles in promoting brain plasticity and treating conditions such as depression and PTSD.
This case adds to emerging discussions about their possible applications in neurodegenerative disorders.
Experts caution that larger, controlled clinical trials are essential to verify safety, efficacy, optimal dosing, and long-term outcomes. Factors such as individual variability, potential risks in elderly patients, and the need for supervised settings must be addressed.
Still, the report fuels optimism that some dementia-related deficits could be more reversible than previously thought.
And most importantly, there is a strong reason to test this with loved ones under medical support than not as the prognosis could not be worse.
As research into psychedelic medicine expands, this case stands as a compelling call for further investigation into how compounds like psilocybin might one day complement existing Alzheimer’s therapies.